Kosterlitz Centre for Therapeutics

Kosterlitz Centre for Therapeutics
Name	Kosterlitz Centre for Therapeutics
Established	2018
Type	Research centre
Parent	University of Aberdeen
Director	Prof. Heather Wilson
Location	Aberdeen, Scotland, United Kingdom
Website	https://www.abdn.ac.uk/ims/kosterlitz-centre/

Kosterlitz Centre for Therapeutics. The Kosterlitz Centre for Therapeutics is a world-leading biomedical research institute within the University of Aberdeen, dedicated to translating fundamental scientific discoveries into novel therapeutic strategies. Established in honor of Nobel laureate Professor Hans Kosterlitz, its mission bridges the gap between laboratory research and clinical application. The centre focuses on understanding disease mechanisms to develop new treatments for conditions including chronic pain, addiction, and neurodegenerative disorders.

History and establishment

The centre was formally launched in 2018, building upon a decades-long legacy of pioneering neuropharmacology research at the University of Aberdeen. Its establishment was catalyzed by the groundbreaking work of Hans Kosterlitz and his colleague John Hughes, who, in the 1970s, discovered the endogenous opioid peptides known as enkephalins at the university. This foundational discovery, for which Kosterlitz later shared the 1988 Nobel Prize with Sir James Black and Gertrude B. Elion, established Aberdeen as a global hub for neuroscience and pharmacology. The creation of the centre was a strategic initiative to consolidate this historic strength, attracting significant investment to create a state-of-the-art facility focused on modern drug discovery. It serves as a living memorial to Kosterlitz's legacy, ensuring his innovative spirit continues to drive therapeutic innovation.

Research focus and therapeutic areas

Research at the centre is strategically organized around understanding the molecular basis of disease to identify new drug targets. A primary focus is on the nervous system, with major programs investigating neuropathic pain, opioid addiction, and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Scientists employ advanced techniques in molecular biology, structural biology, and cheminformatics to study G protein-coupled receptors (GPCRs), ion channels, and neurotransmitter systems. This work extends to exploring the gut-brain axis and its role in disorders like irritable bowel syndrome. The ultimate goal is to develop new classes of analgesics, treatments for substance use disorder, and neuroprotective agents, moving candidates from in vitro studies through to preclinical development.

Key scientific contributions and discoveries

Building directly on the enkephalin discovery, researchers have made significant advances in understanding opioid receptor pharmacology and the development of peptide therapeutics. The centre has contributed to identifying novel signaling pathways involved in chronic pain sensitization, offering potential alternatives to traditional opioids. Work on allosteric modulators for GPCRs has provided new avenues for creating more selective drugs with fewer side effects. Its scientists have also published influential studies on the role of specific ion channels in neuroinflammation and neuronal death, linking these processes to multiple sclerosis and stroke. These contributions are regularly disseminated in high-impact journals such as *Nature* and *PNAS*.

Organizational structure and leadership

The centre operates as an integral part of the University of Aberdeen's Institute of Medical Sciences, fostering close ties with the School of Medicine, Medical Sciences and Nutrition. It is led by a Director, currently Professor Heather Wilson, a renowned expert in neuropharmacology. Research is conducted by several principal investigators leading independent teams, supported by a cadre of postdoctoral researchers, PhD students, and technical staff. The governance structure includes a scientific advisory board comprising international leaders from academia and the pharmaceutical industry, such as representatives from AstraZeneca and GlaxoSmithKline. This structure ensures strategic direction aligns with both scientific excellence and translational potential.

Collaborations and partnerships

The centre maintains a robust network of national and international collaborations to accelerate translational research. It is a key partner in the Innovative Medicines Initiative and several European Union-funded consortia. Locally, it works closely with the NHS Grampian and the Aberdeen Royal Infirmary to facilitate clinical insights and patient-oriented research. Industrial partnerships are central to its model, with ongoing projects and funding agreements with major biotechnology and pharmaceutical companies including Pfizer, Eli Lilly and Company, and Boehringer Ingelheim. These alliances provide crucial resources for high-throughput screening and access to proprietary compound libraries.

Facilities and resources

Housed within the Institute of Medical Sciences building on the Foresterhill campus, the centre boasts cutting-edge infrastructure. Its facilities include dedicated laboratories for cell culture, confocal microscopy, and behavioural neuroscience assays in rodent models. A core drug discovery suite features equipment for automated patch clamp electrophysiology, FACS, and mass spectrometry. Researchers have access to the university's central transgenic services and the Scottish Biologics Facility. The co-location with clinical facilities at Aberdeen Royal Infirmary and the Rowett Institute creates a unique environment that integrates basic science, animal model research, and clinical translation under one roof.

Category:Research institutes in Scotland Category:University of Aberdeen Category:Medical and health organisations based in Scotland Category:Medical research institutes